The U.S. Food and Drug Administration has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).
MacTel is a rare neurodegenerative disease characterized by localized retinal degeneration. Patients with this condition have severe vision loss and alterations of the retinal vasculature.
Revakinagene taroretcel is an encapsulated cell therapy designed to deliver ciliary neurotrophic factor to the retina to slow the progression of the disease. The approval follows positive results from two phase 3 clinical trials showing significant slowing in the loss of macular photoreceptors in patients with MacTel over a 24 month period.
The therapy is the first approved treatment for MacTel. Its expected availability is June 2025.
For more information, click here.
To learn more about rare ophthalmology conditions, visit https://checkrare.com/diseases/ophthalmology-eye-diseases/